Overview

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Status:
Not yet recruiting

Trial end date:
2026-05-22

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Inotuzumab Ozogamicin